215 related articles for article (PubMed ID: 23002206)
1. Halofuginone inhibits the establishment and progression of melanoma bone metastases.
Juárez P; Mohammad KS; Yin JJ; Fournier PG; McKenna RC; Davis HW; Peng XH; Niewolna M; Javelaud D; Chirgwin JM; Mauviel A; Guise TA
Cancer Res; 2012 Dec; 72(23):6247-56. PubMed ID: 23002206
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
3. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis.
Javelaud D; Mohammad KS; McKenna CR; Fournier P; Luciani F; Niewolna M; André J; Delmas V; Larue L; Guise TA; Mauviel A
Cancer Res; 2007 Mar; 67(5):2317-24. PubMed ID: 17332363
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
Mohammad KS; Javelaud D; Fournier PG; Niewolna M; McKenna CR; Peng XH; Duong V; Dunn LK; Mauviel A; Guise TA
Cancer Res; 2011 Jan; 71(1):175-84. PubMed ID: 21084275
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer.
Chen Y; Liu W; Wang P; Hou H; Liu N; Gong L; Wang Y; Ji K; Zhao L; Wang P
Oncotarget; 2016 Nov; 7(44):71341-71352. PubMed ID: 27533085
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.
Juárez P; Fournier PGJ; Mohammad KS; McKenna RC; Davis HW; Peng XH; Niewolna M; Mauviel A; Chirgwin JM; Guise TA
Oncotarget; 2017 Oct; 8(49):86447-86462. PubMed ID: 29156807
[TBL] [Abstract][Full Text] [Related]
7. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.
Gnainsky Y; Kushnirsky Z; Bilu G; Hagai Y; Genina O; Volpin H; Bruck R; Spira G; Nagler A; Kawada N; Yoshizato K; Reinhardt DP; Libermann TA; Pines M
Cell Tissue Res; 2007 Apr; 328(1):153-66. PubMed ID: 17180598
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone enhances the radiation sensitivity of human tumor cell lines.
Cook JA; Choudhuri R; Degraff W; Gamson J; Mitchell JB
Cancer Lett; 2010 Mar; 289(1):119-26. PubMed ID: 19713035
[TBL] [Abstract][Full Text] [Related]
9. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.
Cui Z; Crane J; Xie H; Jin X; Zhen G; Li C; Xie L; Wang L; Bian Q; Qiu T; Wan M; Xie M; Ding S; Yu B; Cao X
Ann Rheum Dis; 2016 Sep; 75(9):1714-21. PubMed ID: 26470720
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone.
Xavier S; Piek E; Fujii M; Javelaud D; Mauviel A; Flanders KC; Samuni AM; Felici A; Reiss M; Yarkoni S; Sowers A; Mitchell JB; Roberts AB; Russo A
J Biol Chem; 2004 Apr; 279(15):15167-76. PubMed ID: 14732719
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
Yee KO; Connolly CM; Pines M; Lawler J
Cancer Biol Ther; 2006 Feb; 5(2):218-24. PubMed ID: 16418571
[TBL] [Abstract][Full Text] [Related]
13. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy.
Sato S; Kawamura H; Takemoto M; Maezawa Y; Fujimoto M; Shimoyama T; Koshizaka M; Tsurutani Y; Watanabe A; Ueda S; Halevi K; Saito Y; Yokote K
Biochem Biophys Res Commun; 2009 Feb; 379(2):411-6. PubMed ID: 19114027
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M; Jakubikova J; Klippel S; Mitsiades CS; Hideshima T; Tai YT; Leiba A; Pines M; Richardson PG; Nagler A; Anderson KC
Br J Haematol; 2012 Jun; 157(6):718-31. PubMed ID: 22533681
[TBL] [Abstract][Full Text] [Related]
15. GLI2-mediated melanoma invasion and metastasis.
Alexaki VI; Javelaud D; Van Kempen LC; Mohammad KS; Dennler S; Luciani F; Hoek KS; Juàrez P; Goydos JS; Fournier PJ; Sibon C; Bertolotto C; Verrecchia F; Saule S; Delmas V; Ballotti R; Larue L; Saiag P; Guise TA; Mauviel A
J Natl Cancer Inst; 2010 Aug; 102(15):1148-59. PubMed ID: 20660365
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.
Dunn LK; Mohammad KS; Fournier PG; McKenna CR; Davis HW; Niewolna M; Peng XH; Chirgwin JM; Guise TA
PLoS One; 2009 Sep; 4(9):e6896. PubMed ID: 19727403
[TBL] [Abstract][Full Text] [Related]
17. Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.
Huo S; Yu H; Li C; Zhang J; Liu T
Int J Clin Exp Pathol; 2015; 8(12):15863-70. PubMed ID: 26884857
[TBL] [Abstract][Full Text] [Related]
18. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
[TBL] [Abstract][Full Text] [Related]
19. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.
Page JM; Merkel AR; Ruppender NS; Guo R; Dadwal UC; Cannonier S; Basu S; Guelcher SA; Sterling JA
Biomaterials; 2015 Sep; 64():33-44. PubMed ID: 26115412
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
